Investors in Iot

Created over 20 years ago, Andera Partners is a major player in private company investments in France and internationally. Its teams manage over €3.6 billion in investments in life sciences (Andera Life Sciences), growth and buyout capital (Andera MidCap, Andera Expansion, Andera Croissance, Andera Co-Invest), sponsorless transactions (Andera Acto) and ecological transition (Andera Infra). Andera Partners’ mission is to work alongside companies and their managers to support them in achieving strong and sustainable growth. The quality of performance offered to our investors relies on a strong partnership between the entrepreneurs in our portfolio companies and our teams, based on shared values. Performance through collective engagement, the “Power of And”, constitutes Andera Partners’ DNA. Based in Paris, with offices in Antwerp and Munich, Andera Partners is wholly owned by its teams, which count nearly 95 professionals, of which 58 investment professionals. It is structured as a partnership and managed by a board of 10 partners. Responsible and committed, the management company regularly forms partnerships with non-profit sector entities and takes concrete action in the fight against global warming. Andera Partners has been certified carbon neutral since 2018.

eureKARE is a visionary investment firm dedicated to advancing synthetic biology innovation throughout Europe. With a firm belief in the transformative potential of synthetic biology to address global health and environmental challenges, eureKARE's seasoned team is committed to leveraging Europe's burgeoning expertise in this field. By pioneering a novel startup creation and development model, eureKARE fosters a vibrant ecosystem of early and later-stage ventures through its network of biotech studios. These studios serve as pivotal bridges between academia and industry, accelerating innovations into robust companies equipped to thrive and deliver societal benefits.

PSV cares about a conscious future. As a venture house, our mission is to clear the path for founders who build companies that matter. Our hybrid setup, comprising PSV Foundry, PSV Lab, and two unique venture funds, PSV Tech and PSV DeepTech, sets us free from adhering to a singular method. Rather we rethink existing ways and models to maximise our impact beyond any individual firm or investment.

KAYA is an early-stage VC fund with roots in CEE, investing in intrepid founders across Europe since 2010. KAYA VC predominantly invests at the seed stage, but there is a growing focus on pre-seed opportunities. They have co-created seven ventures so far and are always seeking new studio projects. Even if an idea is still in its early stages, it is not too early to engage with them. For Seed+, Series A/A+, and businesses with revenue ranging from 0 to €5 million, they are open to making an initial investment. Recognizing the uniqueness of each situation, their initial investment can range from €100,000 to €3 million. KAYA VC has the capacity to invest over €20 million per company over time, leveraging their flagship fund and LPs. They prioritize potential over ownership percentages, preferring to hold 5% of a future unicorn rather than none.

Kurma Partners is a leading European venture capital group specializing in healthcare, managing €470 million in assets. Our firm operates through two dedicated franchises: Kurma Biofund, which focuses on therapeutics (currently active with fund KBIII), and Kurma Diagnostics, which focuses on diagnostic and digital health (currently active with fund Kurma Dx2). We are committed to supporting innovation in healthcare by investing in promising companies that are poised to make significant advancements in therapeutic treatments and diagnostic technologies.

Integra Holdings is a unique venture fund that combines academic excellence, funding and R&D guidance together with a strong and proven business network — the most important elements necessary to bring academic innovation to the market. Focusing on an exclusive selection of biotech companies with proprietary solutions and a competitive advantage in their respective fields, Integra takes a hands-on approach by providing our portfolio companies the strategic planning and business development necessary to bring their technology to the market. Founded by Yissum, the Hebrew University's technology transfer company, Integra capitalizes on the innovative applied research constantly flowing from the renowned Hebrew University of Jerusalem, Israel.

North-East was established in 2013 in Copenhagen by Winnie Liljeborg and Per Algot Enevoldsen, the founders of the global jewelry brand, Pandora. Today they, together with their son, Christian Algot Enevoldsen, are the owners of the family office. The purpose of North-East Family Office is to assist the families in preserving their material and ethical values for the benefit and enjoyment of future generations.

We support early-stage biotech and longevity-focused founders that are changing the world. We help these companies gain industrial momentum, raise capital, and shape the future of biotech. Our approach is based on growing the whole ecosystem. We fund companies in complementary industrial sectors, empowering us to build a broad community of biotech innovators that can exchange their expertise and build on each other's successes.

Nextech is a global, cancer therapeutics-focused venture capital firm headquartered in Zurich, Switzerland. We focus almost exclusively on oncology therapeutics, and on helping to drive value creation for our portfolio companies. We invest in the most promising drug discovery companies with the potential to create multiple medicines. Our portfolio is focused throughout the US and Europe with investments from company inceptions to crossover rounds. Finding and fueling tomorrow's advances in precision medicine.

Springtide Ventures is a venture capital company that helps to bring start-ups to life, materialize their visions, and global ambitions.Springtide Ventures s.r.o., a member of the KKCG group, is a venture capital and private equity firm with a vision to create lasting values through strong partnerships.They invest in SaaS companies specializing in Cyber Security, Cloud Infrastructure.

Science Ventures is developing new high tech start-ups in close collaboration with researchers, industry and investors.Science Ventures Denmark A/S develops deep tech spin outs from SDU in collaboration with researchers, investors, and industry. Their spin outs have created over 1,500 high tech jobs and attracted more than 3 billion DKK in investments.

Since 1998, we at Auriga Partners have supported entrepreneurs from the creation of their company through all stages of development, up to their exit via merger and acquisition or IPO. As pioneers in venture capital in France, we have reinvented ourselves into a multi-specialist investor, dedicated to bringing together specific expertise on future themes or territories—both in unlisted and listed companies.